Medication non-adherence is complex and multi-factorial. Once or twice daily dosing regimens are associated with significantly better medication adherence rates than thrice daily dosing. 5 However, dosing frequency is not the only contributing factor, as multiple factors are associated with medication non-adherence in IBD including full time employment and depression 6 ; history of greater than four concomitant medications and male gender. 3 In addition, other demographic factors such as young age and single status, psychological variables such as medication beliefs and low level of the personality trait of agreeableness, and having high scores on the Obstacles to Medication Use Scale (such as forgetfulness, fear of side effects and costliness) are good predictors of low adherence. 7 Therefore, when developing treatment strategies to optimise adherence, both physician and patient relatedfactors should be considered. Some practical ways of facilitating this are shown in Table 1 . [8] [9] [10] [11] The physicianpatient relationship plays a central role in identifying and addressing patient concerns about their medication. Proactive listening by physicians encourages open dialogue and allows a better understanding of patient medication beliefs, which in turn can help physicians recognise signs of medication non-adherence. 8 Improving patient education through the provision of materials, 9 offering practical advice on the use of cues to remind patients to take their medication, and directing patients to additional support from specialist nurses or patient groups, such as the National Association of Colitis and Crohn's disease (NACC), can be beneficial (Table 1) .
Improving medication adherence rates is a challenge in UC. An understanding of the multiple factors involved and a coordinated approach from the multidisciplinary care team can help to determine the most appropriate treatment strategy for patients, which helps to improve patient outcomes, minimising the potentially debilitating effects of UC. Ensuring patient adherence to medications requires time and commitment, but attention to the different factors mentioned in Table 1 may help. Identification of patients at risk of non-adherence early on in their contact with health carers, and adopting an appropriate strategy to prevent nonadherence, may be a very valuable investment of time.
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